Boston

Health

Can a new Lyme disease vaccine overcome a history of distrust and failure?

By Brittany Flaherty

Adam's Take

FDA’s Sarepta rejection is rooted in the past, and will weigh on its future

By Adam Feuerstein

Cambridge: Sarepta
Biotech

Sarepta stumbles on FDA rejection of a new drug to treat Duchenne muscular dystrophy

By Adam Feuerstein

Something ventured illo
Something Ventured

Compass Therapeutics and these three other biotech startups got venture funding a year ago. Where are they now?

By Kate Sheridan

Sarepta - Cambridge -AP
Biotech

As Sarepta awaits approval of new Duchenne drug, big questions hang over therapy already on market

By Adam Feuerstein

Jeffrey Leiden
Biotech

Vertex, known for cystic fibrosis drugs, sets its sights on taming pain

By Jonathan Saltzman — Boston Globe

In the Lab

The entire human brain in ‘unprecedented’ detail, thanks to powerful MRI

By Sharon Begley

Marisa Boidi
Biotech

Toddler denied $2.1m gene therapy will now get it for free

By Jonathan Saltzman — Boston Globe

Vertex
Pharmalot

Scotland tells Vertex its cystic fibrosis drugs are not cost-effective

By Ed Silverman

Adam's Take

Sarepta’s bad week raised questions about its gene therapy program. Here are some answers

By Adam Feuerstein

Seeding Labs
In the Lab

New life of lab equipment makes science possible for researchers returning to their home countries

By Diana Cai

Sarepta - Cambridge -AP
Biotech

Sarepta’s stock price plummets after an ‘erroneous’ report

By Kate Sheridan

Human T lymphocyte
Biotech

‘Every man and his dog’ does cell therapy. Vor’s new CEO says the company wants to be different

By Kate Sheridan

Adam's Take

Show us the data: Bluebird raises questions by sitting on results of CAR-T drug critical to its future

By Adam Feuerstein

Maura Healey
Health

Purdue Pharma seeks to minimize its role in opioid crisis as it urges dismissal of Massachusetts suit

By Andrew Joseph

Briefcase full of money
Biotech

Life sciences VC firm Vida Ventures raises $600 million in second fund

By Kate Sheridan

In the Lab

You’ve swum with one, stepped on one, maybe swallowed one. This unsung invertebrate could teach us about aging

By Eric Boodman

Dr. Feng Zhang Broad Inst
Exclusive

The latest CRISPR patent fight is on. So is the mudslinging

By Sharon Begley

NIH
In the Lab

NIH-funded project aims to build a ‘Google’ for biomedical data

By Ruth Hailu

F*!@ Disease
Biotech

A mysterious startup launched with an impossibly ambitious rallying cry. Now its plans are coming into focus

By Kate Sheridan

Monthly pills
Biotech

This company wants to make a once-a-month option for birth control pills

By Megan Thielking

A dosage of Spinraza.
Pharmalot

Consumer groups urge Italian and Belgian authorities to investigate Biogen over Spinraza pricing

By Ed Silverman

Gene Editing Blindness
Biotech

First CRISPR study inside the body to start in U.S.

By Associated Press

Vertex
Biotech

Vertex Pharmaceuticals’ Jeffrey Leiden to step aside as CEO

By Matthew Herper

Steven Pearson
Biotech

Patients, backed by ‘dark money’ group, get ready to debate Duchenne drug prices. It will not be boring

By Kate Sheridan

Jeff Jonas
Biotech

Sage Therapeutics to pursue high-risk, high-reward plan for experimental depression pill

By Adam Feuerstein

Charlie Baker
Pharmalot

Massachusetts lawmakers approve compromise bill to lower Medicaid drug spending

By Ed Silverman

Ear Hair Cells
Biotech

Frequency Therapeutics raises another $62 million

By Jonathan Saltzman — Boston Globe

Health

Study: Millions should stop using aspirin for heart health

By Associated Press

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy